Search clinical trials for: Acarbose/Metformin (Glucobay M, BAY81-9783)

Total 12 results

Bayer

Withdrawn

GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice (GLORY)

Diabetes Mellitus, Type 2
Bayer

Completed

GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients (GLOBE)

Type 2 Diabetes

India
Bayer

Completed

Bioequivalence Study for Acarbose / Metformin FDC

Diabetes Mellitus, Type II

Korea, Republic of
Bayer

Completed

Bioequivalence Study for Acarbose/Metformin FDC

Diabetes Mellitus, Type 2

China
Bayer

Active, not recruiting

A Study to Learn More About How Acarbose and Metformin Work When Taken Together and How Safe They Are in Indian Patients Who Were Recently Diagnosed With Type 2 Diabetes (T2D) (START-AM)

Type 2 Diabetes Mellitus

India
Bayer

Withdrawn

Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy (STARCH AM)

Diabetes Mellitus
Shanghai 6th People's Hospital

Unknown

the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin (CGMS)

Type 2 Diabetes

China
Takeda

Completed

Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Unknown

Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus
Sanofi

Completed

Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (SWITCH)

Type 2 Diabetes Mellitus

China
Sanofi

Completed

Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive (ACADEMIC)

Type 2 Diabetes Mellitus

China
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

Type 2 Diabetes Mellitus

3

Subscribe